Drug Information for WATSON PHARMARevised: June 2005IN-5260/SPHYSICIAN LABELING Brevicon (Norethindrone and Ethinyl Estradiol Tablets USP, 0.5 mg/0.035 mg) Norinyl 1+35 (Norethindrone and Ethinyl Estradiol Tablets USP, 1 mg/0.035 mg) Norinyl 1+50 (Norethindrone and Mestranol Tablets USP, 1 mg/0.05 mg) Rx Only (Watson Pharma, Inc.): NON-CONTRACEPTIVE HEALTH BENEFITS

  • The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of menstranol.6-11

    Effects on menses:

    • Increased menstrual cycle regularity

    • Decreased blood loss and decreased incidence of iron deficiency anemia

    • Decreased incidence of dysmenorrhea

    Effects related to inhibition of ovulation:

    • Decreased incidence of functional ovarian cysts

    • Decreased incidence of ectopic pregnancies

    Effects from long-term use:

    • Decreased incidence of fibroadenomas and fibrocystic disease of the breast

    • Decreased incidence of acute pelvic inflammatory disease

    • Decreased incidence of endometrial cancer

    • Decreased incidence of ovarian cancer

    Keep this and all medication out of the reach of children.

  • Drug Information Provided by National Library of Medicine (NLM).